News

Aethlon Medical Plans Engaging Presentations This September

Aethlon Medical Plans Engaging Presentations This September

Aethlon Medical's Upcoming Virtual Investor Conferences

Aethlon Medical, Inc. (NASDAQ: AEMD) is committed to developing cutting-edge therapies for cancer and serious infectious diseases, and they have some exciting news for their investors. In September, they're set to present at two important virtual investor conferences where they will discuss their latest developments and engage with the investment community.

Life Sciences Investor Forum Presentation

On September 19 and 20, Aethlon Medical's interim CEO and CFO, James Frakes, along with Dr. Steven LaRosa, the company's Chief Medical Officer, will provide an overview of the company during the Life Sciences Investor Forum. This virtual conference will allow for direct interaction between investors and the company's management team.

Details of the Life Sciences Investor Forum

The presentation is confirmed for September 19, 2024, at 1:30 pm ET. Investors interested in attending can pre-register for the event, which includes the opportunity to pose questions in real-time directly to the management team. Additionally, an archived version of the presentation will be made available afterward for those who wish to revisit the conversation.

Insights from the Virtual Emerging Growth Conference

Following the Life Sciences Investor Forum, Aethlon Medical will also participate in the Virtual Emerging Growth Conference on September 25, 2024. The same leadership team will again reveal essential insights into the company's strategic directions and advancements in their medical therapies.

Presentation Insights for the Emerging Growth Conference

This particular presentation is scheduled to take place on September 25, 2024, at 12:35 pm ET. After the session, there will be an opportunity for questions, enabling investors to further engage with the leadership of Aethlon Medical. Investors can send in questions beforehand, leading to a lively and interactive Q&A segment during the conference.

Aethlon Medical and Their Innovations

Aethlon Medical is at the forefront of developing the Hemopurifier, a vital medical device aimed at addressing both cancer and life-threatening viral infections. This innovative device has been through several studies, showing its ability to remove harmful viruses and exosomes from biological fluids, utilizing a one-of-a-kind lectin-based technology.

The Impact of the Hemopurifier

The Hemopurifier has been designated as a Breakthrough Device by the U.S. FDA, highlighting its significant potential in treating advanced or metastatic cancers, particularly in cases where patients have not responded to traditional treatments. Furthermore, this device also has an open Investigational Device Exemption (IDE) application for addressing dangerous viruses that currently lack approved treatment options.

Company Insights and Future Directions

Aethlon Medical is dedicated to meeting the unmet medical needs in the fields of cancer and infectious diseases. The upcoming presentations will offer valuable insights into their strategic initiatives, aimed at positioning the company advantageously within a competitive landscape. Investors are encouraged to engage with the leadership team during these two virtual conferences to gain a deeper understanding of Aethlon's evolving role in healthcare innovation.

Contact Information for Inquiries

For further questions or information, investors can reach out to:

Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

Frequently Asked Questions

What will Aethlon Medical present at the conferences?

Aethlon Medical will discuss company overviews and new innovations, particularly focusing on their Hemopurifier technology.

When are the scheduled presentations?

The presentation at the Life Sciences Investor Forum is on September 19, and the session for the Virtual Emerging Growth Conference is on September 25, both occurring in 2024.

Who is presenting for Aethlon Medical?

James Frakes, the Interim CEO and CFO, along with Dr. Steven LaRosa, the Chief Medical Officer, will be presenting at both events.

How can investors interact with the company during the conferences?

Investors can participate in Q&A sessions throughout the conferences and are able to submit questions beforehand to the management team.

What is the purpose of the Hemopurifier?

The Hemopurifier is designed specifically to target and eliminate life-threatening viruses and exosomes, offering support for patients battling cancer and severe infections.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 20

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 83

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 58

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 0

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 138

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading

Top 5 Most Recently Viewed Articles

MAGNA-TILES Unveils Exciting Rail Racers To Transform Play

Updated Category News Views 562

MAGNA-TILES Innovates Play with Rail Racers Launch First Fan-Made Invention Reimagines Ball Runs and Takes Magnetic Building to the Next Level MAGNA-TILES, America’s favorite magnetic building toy brand, has introduced an exciting innovation—the Rail Racers. This remarkable new product debuted at the American International Toy Fair, showcasing the creativity of the...

Continue Reading
Discover DDB Miner’s Innovative Approach to Bitcoin Mining

Updated Category News Views 167

Unlocking the Future of Bitcoin Mining DDB Miner, a forward-thinking Bitcoin mining entity, is making significant strides in the cryptocurrency industry. By emphasizing low-cost and efficient operations, DDB Miner is set on a path to redefine how Bitcoin is mined. Their latest operational update sheds light on impressive developments and ambitious plans that promise to...

Continue Reading
Warren Buffett Plans Charitable Giving with New CEO Transition

Updated Category News Views 217

Warren Buffett Speeds Up Charitable Contributions Warren Buffett recently announced that he will accelerate the distribution of his vast fortune, amounting to $149 billion, to his children's charitable foundations. This strategic decision aligns with the responsibilities he feels as a father, recognizing the increasing ages of his children. The Transition to Greg Abel As...

Continue Reading
Understanding the DeFi Technologies Class Action and Its Impact

Updated Category News Views 238

DeFi Technologies Class Action Explained Robbins LLP recently brought to light a class action lawsuit on behalf of investors who bought or acquired shares of DeFi Technologies Inc. (NASDAQ: DEFT). This action covers a specific timeframe, reflecting concerns over the company’s alleged misrepresentation of its business prospects. Investors seeking clarity on this...

Continue Reading
Alibaba's Robotics Innovation: Shaping the Future of AI Tech

Updated Category News Views 199

Alibaba's Bold Move into Robotics Alibaba Group (NYSE: BABA) has embarked on an exciting new venture by launching its own robotics team to compete in the rapidly advancing field of AI-powered physical products. This initiative reflects Alibaba's commitment to integrating artificial intelligence into everyday applications, transforming how technology interacts with the...

Continue Reading